As part of the June 7th-9th RESI conference four panelists moderated by Rachel Zolot Schwartz of Volostra Therapeutics gathered to discuss alternatives to big pharma partners when wanting to do development deals as a small firm.

The speakers include:

• Kevin Lin (Transcenta Holding) 
• Carla Lema Tomé (Spark Therapeutics)
• Ian Mehr (Kowa Research Institute) 
• Sa’ar Yaniv (Journey Medical)

To start off the discussion the panel put in their ideas about the market’s condition and if it is changing their outlook on deal making. The panel provided an optimistic outlook for companies looking to get funding in the current market. As a rule, market capitalizations are falling and generally lowering the average market cap needed to be seen as a company worth examining. According to the panelists $25million market capitalization is sufficient in some cases to enter a pipeline for a deal.